Author:
Shimizu Ryosuke,Sonoyama Takuhiro,Fukuhara Takahiro,Kuwata Aya,Matsuo Yumiko,Kubota Ryuji
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference24 articles.
1. World Health Organization. WHO Coronavirus Dashboard. 2022. https://covid19.who.int/. Accessed 28 Feb 2023.
2. Unoh Y, Uehara S, Nakahara K, Nobori H, Yamatsu Y, Yamamoto S, et al. Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J Med Chem. 2022;65:6499–512. https://doi.org/10.1021/acs.jmedchem.2c00117.
3. Xocova® (Ensitrelvir Fumaric Acid) tablets 125 mg approved in Japan for the treatment of SARS-CoV-2 infection, under the emergency regulatory approval system [press release, 22 Nov 2022. https://www.shionogi.com/global/en/news/2022/11/e20221122.html. Accessed 17 Dec 2022.
4. Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, et al. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. Nature. 2022;607(7917):119–27. https://doi.org/10.1038/s41586-022-04856-1.
5. Kawashima S, Matsui Y, Adachi T, Morikawa Y, Inoue K, Takebayashi S, et al. Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally. Biochem Biophys Res Commun. 2023;645:132–6. https://doi.org/10.1016/j.bbrc.2023.01.040.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献